These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25816669)

  • 21. Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma.
    Lukenda A; Dotlic S; Vukojevic N; Saric B; Vranic S; Zarkovic K
    J Clin Pathol; 2016 Mar; 69(3):234-9. PubMed ID: 26290260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma.
    Pătraşcu AM; Rotaru I; Olar L; Pătraşcu Ş; Ghiluşi MC; NeamŢu SD; Nacea JG; Gluhovschi A
    Rom J Morphol Embryol; 2017; 58(3):837-843. PubMed ID: 29250662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
    Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
    Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
    Smolewski P; Robak T; Krykowski E; Blasiñska-Morawiec M; Niewiadomska H; Pluzanska A; Chmielowska E; Zambrano O
    Clin Cancer Res; 2000 Mar; 6(3):1150-60. PubMed ID: 10741746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
    Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
    J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [KI-1-positive, anaplastic, large-cell lymphoma related to Hodgkin's disease].
    Veiga M; Fresno MF; Pérez del Río MJ; García I; Madrigal B; Herrero A
    Sangre (Barc); 1997 Feb; 42(1):81-4. PubMed ID: 9229809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High expression of minichromosome maintenance protein 6 in classic Hodgkin's lymphoma points to a cell cycle arrest in G1 phase.
    Karimi S; Mohammadi F; Khodadad K; Emami H; Seyfollahi L
    Arch Iran Med; 2008 Sep; 11(5):532-8. PubMed ID: 18759521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The expression and clinical significance of proliferative antigen Ki-67 and apoptosis-antagonizing antigen Bcl-2 in non-Hodgkin's lymphoma].
    Xu W; Sheng R; Zheng Z; Xu T
    Zhonghua Nei Ke Za Zhi; 2001 Jul; 40(7):452-5. PubMed ID: 11798613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
    Miettinen M
    Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression and significance of B-cell-specific activator protein of H/RS cell in classical Hodgkin's Lymphoma].
    Zhou X; Zhao T; Qi Z; Liu G; Zhu M
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1532-5. PubMed ID: 12609061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of K-1 (CD-30) marker in Hodgkin's disease.
    Shakoor KA; Saleh A; Khanzada MS
    J Pak Med Assoc; 2002 Oct; 52(10):442-7. PubMed ID: 12553671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.
    Gharbaran R; Goy A; Tanaka T; Park J; Kim C; Hasan N; Vemulapalli S; Sarojini S; Tuluc M; Nalley K; Bhattacharyya P; Pecora A; Suh KS
    J Hematol Oncol; 2013 Aug; 6():62. PubMed ID: 23988031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
    Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.
    Chatzitolios A; Venizelos I; Tripsiannis G; Anastassopoulos G; Papadopoulos N
    Ann Hematol; 2010 Sep; 89(9):889-96. PubMed ID: 20352431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas.
    Doglioni C; Pelosio P; Mombello A; Scarpa A; Chilosi M
    Hematol Pathol; 1991; 5(2):67-73. PubMed ID: 1680118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [PROGNOSTIC RISK FACTORS FOR NEWLY DIAGNOSED PATIENTS WITH ADVANCED STAGES CLASSICAL HODGKIN'S LYMPHOMA].
    Novosad OI; Kriachok IA; Grabovyy OM; Antonuk SA
    Lik Sprava; 2014; (9-10):88-94. PubMed ID: 26492782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type.
    Asano N; Kinoshita T; Tamaru J; Ohshima K; Yoshino T; Niitsu N; Tsukamoto N; Hirabayashi K; Izutsu K; Taniwaki M; Morishima Y; Nakamura S
    Haematologica; 2011 Nov; 96(11):1636-43. PubMed ID: 21859738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
    Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
    PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.